Fig. 6

Flow cytometry analysis of T cell-/lymphocyte-specific markers on normal and malignant B cells from CLL patients. a Summary scheme representing functional implications of CLL-specific candidate genes selected for flow cytometric analysis. b Flow cytometric analysis of expression of CTLA-4, TIGIT, CD276, LILRB4, and CD2 on peripheral blood B cells of CLL patients. The expression was determined for non-malignant B cells (“Normal”; CD19⁺ CD5⁻ B cells, represented in green) and neoplastic B cells (“CLL”, CD19⁺ CD5⁺ B cells, represented in orange) detected in the same samples. “Co,” no antibody staining control; “Ab,” staining with the antibody of interest as indicated. c Normalized median fluorescence intensities (target MFI - MFI of negative control [Co]; nMFI). d Δ normalized median fluorescence intensities between CLL cells and normal B cells (ΔnMFI (CLL-normal)) for each patient tested